Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

(PWRME, CHFC, ININ, BCPC) Stock under Consideration by Stock-PR.com

<p align="center">Stock-PR Reporting</p>
<p align="center"><a title="Stock-PR website" href="stock-pr.com&quot; target="_blank"><img class="alignnone size-full wp-image-2414" title="stockpr_logo-site" alt="stockpr_logo-site" src="stock-pr.com/img/stockpr_logo-site.jpg&quot; /></a></p>
<p align="center"> </p>
<p align="center"><strong><a title="free stock alerts, best stock alerts, hot stock alerts, stock picks, best stock picks, free stock picks" href="pennyomega.com/?page_id=835&quot;></a></strong></p>
<p align="center"><strong><span style="COLOR: black">FREE Daily Stock Alerts From Stock-PR.com</span></strong></p>
<p style="TEXT-ALIGN: center"> </p>
<p align="center"><a title="free stock alerts, best stock alerts, hot stock alerts, stock picks, best stock picks, free stock picks" href="stock-pr.com/?page_id=1085&quot;></a></p>
<p align="center"><span style="COLOR: black"><strong><span style="COLOR: black"><strong><span style="COLOR: rgb(0,128,255)"><span style="COLOR: rgb(0,128,255)"><a title="stock-pr sign up" href="stock-pr.com/signup&quot; target="_blank"><img height="90" alt="chartstockalert" src="pennyomega.com/img/chartstockalert.jpg&quot; width="360" /></a></span></span></strong></span></strong></span></p>
<p align="center"> </p>
<p><span style="COLOR: black"><span style="COLOR: black"><span style="COLOR: rgb(0,128,255)"><span style="COLOR: rgb(0,128,255)"><font color="black"><strong><img style="WIDTH: 132px; HEIGHT: 57px" height="63" alt="power3" hspace="0" src="pennyomega.com/img/power3.png&quot; width="152" align="bottom" border="0" mce_src="pennyomega.com/img/power3.png&quot; /> Power3 Medical Products, Inc. (PWRME.OB)<br /></strong><br />
The NuroPro Blood Test is Power3 Medical's medical diagnostic tool for the early detection of Neurodegenerative diseases. The analysis is designed as a tool for physicians to diagnose various degenerative diseases of the brain and nervous system. The test involves monitoring the concentration of 59 proteins in blood serum to accurately detect and distinguish between Alzheimer's disease, ALS (Lou Gehrig's disease), and Parkinson's disease. Early detection of these diseases will allow physicians to intervene at an early stage to delay disease progression, potentially allowing patients to outlive their debilitating symptoms.<br />
<br />
Parkinson's disease (PD) mainly develops in people over the age of 50. It becomes more common with increasing age. PD is not usually inherited, and it can affect anyone. However, genetic (hereditary) factors may be important in the small number of people who develop the disease before the age of 50. If you have PD, a number of cells in the substantia nigra become damaged and die. The exact cause of this is not known. Over time, more and more cells become damaged and die. As cells are damaged, the amount of dopamine that is produced is reduced. A combination of the reduction of cells and a low level of dopamine in the cells in this part of the brain causes nerve messages to the muscles to become slowed and abnormal.</font></span></span></span></span></p>
<p><span style="COLOR: black"><span style="COLOR: black"><span style="COLOR: rgb(0,128,255)"><span style="COLOR: rgb(0,128,255)"><font color="black"><strong>Power3 Medical Products, Inc</strong>. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig's disease). Power3 Medical applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 Medical has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer's, Parkinson's, and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual's proteins to detect the presence of disease, a patient's disease progression, a patient's response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.</font></span></span></span></span></p>
<p><span style="COLOR: black"><span style="COLOR: black"><span style="COLOR: rgb(0,128,255)"><span style="COLOR: rgb(0,128,255)"><font color="black">Please visit Power3 Medical Products, Inc website</font> <a href="www.power3medical.com&quot;><font color="black">www.power3medical.com&lt;/font></a><font color="black">.<br />
<br />
*************************************************************************************<br />
<br />
<strong>Chemical Financial Corp. (Nasdaq:CHFC)</strong> announced 2011 first quarter net income of $9.2 million, or $0.33 per diluted share, compared to 2010 fourth quarter net income of $7.5 million, or $0.27 per diluted share, and $2.3 million, or $0.10 per diluted share, in the first quarter of 2010.<br />
<br />
Chemical Financial Corporation operates as the holding company for Chemical Bank that offers commercial banking services in Michigan.<br />
<br />
******************************************<br />
<br />
<strong>Interactive Intelligence, Inc. (Nasdaq:ININ)</strong> has announced operating results for the three months ended March 31, 2011. The company reported revenues of $47.7 million, an increase of 36 percent from revenues of $35.0 million in the first quarter of 2010. Product revenues increased by 32 percent, recurring revenues by 30 percent, and services revenues by 88 percent compared to the 2010 first quarter.<br />
<br />
Interactive Intelligence, Inc. provides software application suites for voice over Internet protocol (VoIP) business communications to enterprises in the United States and internationally.<br />
<br />
******************************************<br />
<br />
<strong>Balchem Corp. (Nasdaq:BCPC)</strong> announced that a conference call will be held on Tuesday, May 3, 2011 at 11:00 AM Eastern Time (NYSE:ET) to review first quarter 2011 results. Dino A. Rossi, Chairman, President and CEO, and Frank Fitzpatrick, Chief Financial Officer, will host the call. Quarterly results will be released to the market on Tuesday, May 3, 2011 at 9:30 AM (ET). The press release, and its accompanying financial exhibits, will also be available on the Company website,</font> <a href="www.balchem.com&quot;><font color="black">balchem.com&lt;/font></a><font color="black">, prior to the conference call. We invite you to listen to the conference by calling toll-free 1-877-407-8289 (local dial-in 1-201-689-8341 ), five minutes prior to the scheduled start time of the conference call. The conference call will be available for digital replay through Tuesday, May 10, 2011. To access the replay of the conference call, dial 1-877-660-6853 (local dial-in 1-201-612-7415 ), and use account #298 and replay ID #371411. Both account and replay ID numbers are required for replay access.<br />
<br />
Balchem Corporation provides specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, and medical sterilization industries in the United States and internationally.</font><br /></span></span></span></span></p>
<p align="center"> </p>
<p align="center"> </p>
<p align="center">**************************************************************</p>
<p align="center"><strong>THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!</strong></p>
<p><strong><font color="blue"><font color="red">Disclaimer:</font> Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (<font color="red">Read more at <a href="stock-pr.com/?page_id=40&quot; target="_blank"><font color="red">stock-pr.com/disclaimer&lt;/font></a></font>).</font></strong><span style="COLOR: red"><span style="COLOR: red"><strong><font color="blue">Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.</font><font color="red">Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRME.OB).<br />
<br /></font></strong></span></span></p>
<p align="center">Sign Up For Free Stock Alerts At <a href="stock-pr.com/signup&quot; target="_blank">stock-pr.com/signup&lt;/a></p>
<p align="center"><a href="www.crownequityholdings.com&quot; target="_blank"><img alt="stock-pr.com/img/stock-pr_buscard.jpg&quot; src="stock-pr.com/img/stock-pr_buscard.jpg&quot; /></a></p>